9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Estimated reading time: < 1 min

Condition: Life Threatening Diseases

Estimated Enrollment: 185

Gender: All

Min Age: 15 Years

Age Group: Child, Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases,  To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease,  To assess the safety and tolerability of Imatinib mesylate, To evaluate the pharmacokinetic profile of Imatinib mesylate

Interventions: Imatinib mesylate,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: January 2007

Completion Date: January 2007

Last  Posted Date: November 18, 2016

Location:

Website Link: https://ClinicalTrials.gov/show/NCT00154388

Was this article helpful?
Dislike 0